Literature DB >> 19454394

Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients.

Irl B Hirsch1, Hongbo Yuan, Barbara N Campaigne, Meng H Tan.   

Abstract

OBJECTIVE: To determine whether metformin-treated patients with type 2 diabetes given an analogue mixture of basal and rapid-acting insulins (insulin lispro protamine suspension plus insulin lispro) would have less glycemic variability than patients given basal insulin glargine.
METHODS: Two post hoc analyses were used to compare 7-point blood glucose profiles from 3 published studies comparing basal plus prandial premixed insulin lispro mixtures with insulin glargine in metformin-treated patients with type 2 diabetes. Glycemic variability indices used included standard deviation of mean daily blood glucose, coefficient of variation, M-value, mean amplitude of glycemic excursion, and J-index.
RESULTS: Patients on the twice-daily insulin lispro mix 75/25 (75% insulin lispro protamine suspension/25% insulin lispro) plus metformin regimen had significantly lower standard deviation, M-value, and J-index than patients on the insulin glargine plus metformin regimen, but not lower coefficient of variation or mean amplitude of glycemic excursion. Patients on the 3 times daily insulin lispro mix 50/50 (50% insulin lispro protamine suspension/50% insulin insulin lispro) plus metformin regimen had significantly lower values for all 5 indices than patients on the insulin glargine plus metformin regimen.
CONCLUSION: Use of basal plus prandial insulin lispro mixtures at 2 or 3 meals was associated with lower glycemic variability in metformin-treated patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454394     DOI: 10.4158/EP08308.ORR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  5 in total

Review 1.  Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes.

Authors:  Guillermo E Umpierrez; Boris P Kovatchev
Journal:  Am J Med Sci       Date:  2018-10-02       Impact factor: 2.378

Review 2.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 3.  Combining basal insulin analogs with glucagon-like peptide-1 mimetics.

Authors:  Riccardo Perfetti
Journal:  Diabetes Technol Ther       Date:  2011-06-28       Impact factor: 6.118

4.  Evidence-based clinical use of insulin premixtures.

Authors:  Marcos Antônio Tambascia; Márcia Nery; Jorge Luiz Gross; Mariana Narbot Ermetice; Carolina Piras de Oliveira
Journal:  Diabetol Metab Syndr       Date:  2013-09-06       Impact factor: 3.320

Review 5.  Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations.

Authors:  Gary Deed; Gary Kilov; Trisha Dunning; Richard Cutfield; Jane Overland; Ted Wu
Journal:  Diabetes Ther       Date:  2017-11-07       Impact factor: 2.945

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.